Dependence on partner channels
The company relies on selected corporate partners for market access and sales execution.
- Scope
- European partner markets
- Materiality
- high
iZafe Group
iZafe Group AB is a Swedish health-tech company focused on digital medication management solutions for home care, healthcare providers, and consumers. Its core offering centers on connected pill dispensers, medication adherence tools, and related software and services sold through partner channels and direct consumer sales in selected markets.
| % | |
|---|---|
| Dosell | 45% Connected medication dispenser and associated services for adherence monitoring. |
| Pillbox | 20% Smart pillbox product used to support correct medication timing and adherence. |
| Partner licenses | 25% Recurring license fees from welfare and healthcare partners using iZafe solutions. |
| Consumer subscriptions and hardware | 10% Direct-to-consumer subscriptions and device sales, mainly through online channels. |
iZafe sells mainly through selected corporate partners with local market knowledge, including digital welfare and...
- Healthcare platform partnersprimary
Buy iZafe products and licenses to embed adherence tools into their own care offerings.
- Public healthcare and welfare providersprimary
Use Dosell and related tools to support medication management in home care and elder care.
- Private care providerssecondary
Purchase digital medication solutions to improve service quality and workflow efficiency.
- Consumerssecondary
Buy subscriptions and devices directly for personal medication adherence support.
iZafe is headquartered in Stockholm and operates through partners across several European markets...
- •Headquartered in Stockholm, Sweden
- •Active partner presence in several European markets
- •Sweden is the main direct-to-consumer market
- •Partner-led expansion reduces need for a large sales force
- •Local healthcare rules and reimbursement shape market access
iZafe’s strategy is to scale through local and regional partners that already have healthcare relationships,...
01
Partner-led international expansionmedium-term
Partners provide local market access, healthcare expertise, and distribution reach.
02
Recurring revenue growthshort-term
License and subscription models can improve predictability versus one-time device sales.
03
Broader medication-adherence platformmedium-term
A wider product set increases relevance across different patient and care settings.
iZafe depends on partner execution, healthcare adoption, and market access in each country, so growth can be uneven and...
Healthcare adoption and workflow integration
Medication-adherence tools must fit provider processes and gain user trust before scaling.
- Scope
- Public and private care settings
- Materiality
- high
Commercial concentration
A limited number of products, partners, and markets can make results sensitive to individual wins or losses.
- Scope
- Company-wide
- Materiality
- high
Country-specific regulatory and reimbursement barriers
Digital health products often require local approvals, procurement acceptance, or reimbursement support.
- Scope
- Nordics and Western Europe
- Materiality
- medium
IFRS 15
IFRS 15 revenue recognition
Affects revenue timing and quarterly comparability
Intangible asset and development cost impairment
Can materially affect balance sheet and earnings
Lease accounting
Affects EBITDA-style metrics and leverage presentation
: 11/08/2026